相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2019)
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K-pneumoniae
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2019)
The Infectious Diseases Society of America's 10 x ′20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 x ′20 a Possibility?
George H. Talbot et al.
CLINICAL INFECTIOUS DISEASES (2019)
Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam
Matthaios Papadimitriou-Olivgeris et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials
Simone Lanini et al.
LANCET INFECTIOUS DISEASES (2019)
Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam
Ibai Los-Arcos et al.
INFECTION (2019)
Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series
G. Spoletini et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Analysis of the clinical antibacterial and antituberculosis pipeline
Ursula Theuretzbacher et al.
LANCET INFECTIOUS DISEASES (2019)
Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms
Sameer S. Kadri et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2019)
Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam
Pranita D. Tamma et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime/avibactam plus aztreonam
Gavin Barlow et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul et al.
LANCET INFECTIOUS DISEASES (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Intravenous Colistin Monotherapy versus Combination Therapy against Carbapenem-Resistant Gram-Negative Bacteria Infections: Meta-Analysis of Randomized Controlled Trials
I-Ling Cheng et al.
JOURNAL OF CLINICAL MEDICINE (2018)
The ideal patient profile for new beta-lactam/beta-lactamase inhibitors
Philippe Montravers et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2018)
Colistin for the treatment of multidrug-resistant infections
Kerry LaPlante et al.
LANCET INFECTIOUS DISEASES (2018)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients
Juan J. Caston et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2016)
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections
Marco Falcone et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Tracking Colistin-Treated Patients to Monitor the Incidence and Outcome of Carbapenem-Resistant Gram-Negative Infections
Sameer S. Kadri et al.
CLINICAL INFECTIOUS DISEASES (2015)
Factors affecting the uptake of new medicines: a systematic literature review
Agnes Lubloy
BMC HEALTH SERVICES RESEARCH (2014)
Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2012)
分享论文
